Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Staging biomarkers in preclinical autosomal dominant Alzheimer's disease by estimated years to symptom onset.

Wang G, Coble D, McDade EM, Hassenstab J, Fagan AM, Benzinger TLS, Bateman RJ, Morris JC, Xiong C; Dominantly Inherited Alzheimer Network (DIAN).

Alzheimers Dement. 2019 Feb 14. pii: S1552-5260(18)33625-2. doi: 10.1016/j.jalz.2018.12.008. [Epub ahead of print]

PMID:
30773445
2.

Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.

Gordon BA, Blazey TM, Christensen J, Dincer A, Flores S, Keefe S, Chen C, Su Y, McDade EM, Wang G, Li Y, Hassenstab J, Aschenbrenner A, Hornbeck R, Jack CR Jr, Ances BM, Berman SB, Brosch JR, Galasko D, Gauthier S, Lah JJ, Masellis M, van Dyck CH, Mintun MA, Klein G, Ristic S, Cairns NJ, Marcus DS, Xiong C, Holtzman DM, Raichle ME, Morris JC, Bateman RJ, Benzinger TLS.

Brain. 2019 Feb 11. doi: 10.1093/brain/awz019. [Epub ahead of print]

PMID:
30753379
3.

Persistent metabolic youth in the aging female brain.

Goyal MS, Blazey TM, Su Y, Couture LE, Durbin TJ, Bateman RJ, Benzinger TL, Morris JC, Raichle ME, Vlassenko AG.

Proc Natl Acad Sci U S A. 2019 Feb 4. pii: 201815917. doi: 10.1073/pnas.1815917116. [Epub ahead of print]

4.

Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease.

Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, Gräber S, Kuder-Buletta E, LaFougere C, Laske C, Vöglein J, Levin J, Masters CL, Martins R, Schofield PR, Rossor MN, Graff-Radford NR, Salloway S, Ghetti B, Ringman JM, Noble JM, Chhatwal J, Goate AM, Benzinger TLS, Morris JC, Bateman RJ, Wang G, Fagan AM, McDade EM, Gordon BA, Jucker M; Dominantly Inherited Alzheimer Network.

Nat Med. 2019 Feb;25(2):277-283. doi: 10.1038/s41591-018-0304-3. Epub 2019 Jan 21.

PMID:
30664784
5.

Seizures as an early symptom of autosomal dominant Alzheimer's disease.

Vöglein J, Noachtar S, McDade E, Quaid KA, Salloway S, Ghetti B, Noble J, Berman S, Chhatwal J, Mori H, Fox N, Allegri R, Masters CL, Buckles V, Ringman JM, Rossor M, Schofield PR, Sperling R, Jucker M, Laske C, Paumier K, Morris JC, Bateman RJ, Levin J, Danek A; Dominantly Inherited Alzheimer Network.

Neurobiol Aging. 2018 Dec 5;76:18-23. doi: 10.1016/j.neurobiolaging.2018.11.022. [Epub ahead of print]

PMID:
30616208
6.

Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease.

Wang G, Xiong C, McDade EM, Hassenstab J, Aschenbrenner AJ, Fagan AM, Benzinger TLS, Gordon BA, Morris JC, Li Y, Bateman RJ; Dominantly Inherited Alzheimer Network (DIAN).

Alzheimers Dement (N Y). 2018 Dec 7;4:669-676. doi: 10.1016/j.trci.2018.10.009. eCollection 2018.

7.

Protein production is an early biomarker for RNA-targeted therapies.

Self WK, Schoch KM, Alex J, Barthélemy N, Bollinger JG, Sato C, Cole T, Kordasiewicz HB, Swayze E, Bateman RJ, Miller TM.

Ann Clin Transl Neurol. 2018 Oct 14;5(12):1492-1504. doi: 10.1002/acn3.657. eCollection 2018 Dec.

8.

Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network.

Bussy A, Snider BJ, Coble D, Xiong C, Fagan AM, Cruchaga C, Benzinger TLS, Gordon BA, Hassenstab J, Bateman RJ, Morris JC; Dominantly Inherited Alzheimer Network.

Neurobiol Aging. 2019 Mar;75:42-50. doi: 10.1016/j.neurobiolaging.2018.10.011. Epub 2018 Oct 13.

PMID:
30530186
9.

CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline.

Suárez-Calvet M, Capell A, Araque Caballero MÁ, Morenas-Rodríguez E, Fellerer K, Franzmeier N, Kleinberger G, Eren E, Deming Y, Piccio L, Karch CM, Cruchaga C, Paumier K, Bateman RJ, Fagan AM, Morris JC, Levin J, Danek A, Jucker M, Masters CL, Rossor MN, Ringman JM, Shaw LM, Trojanowski JQ, Weiner M, Ewers M, Haass C; Dominantly Inherited Alzheimer Network; Alzheimer's Disease Neuroimaging Initiative.

EMBO Mol Med. 2018 Dec;10(12). pii: e9712. doi: 10.15252/emmm.201809712.

10.

The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer's disease.

Twohig D, Rodriguez-Vieitez E, Sando SB, Berge G, Lauridsen C, Møller I, Grøntvedt GR, Bråthen G, Patra K, Bu G, Benzinger TLS, Karch CM, Fagan A, Morris JC, Bateman RJ, Nordberg A, White LR, Nielsen HM; Dominantly Inherited Alzheimer Network (DIAN).

Acta Neuropathol Commun. 2018 Nov 26;6(1):130. doi: 10.1186/s40478-018-0624-z.

11.

Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease.

Joseph-Mathurin N, Su Y, Blazey TM, Jasielec M, Vlassenko A, Friedrichsen K, Gordon BA, Hornbeck RC, Cash L, Ances BM, Veale T, Cash DM, Brickman AM, Buckles V, Cairns NJ, Cruchaga C, Goate A, Jack CR Jr, Karch C, Klunk W, Koeppe RA, Marcus DS, Mayeux R, McDade E, Noble JM, Ringman J, Saykin AJ, Thompson PM, Xiong C, Morris JC, Bateman RJ, Benzinger TLS; Dominantly Inherited Alzheimer Network.

Alzheimers Dement (Amst). 2018 Sep 27;10:669-677. doi: 10.1016/j.dadm.2018.08.012. eCollection 2018.

12.

Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease.

Müller S, Preische O, Sohrabi HR, Gräber S, Jucker M, Ringman JM, Martins RN, McDade E, Schofield PR, Ghetti B, Rossor M, Fox NN, Graff-Radford NR, Levin J, Danek A, Vöglein J, Salloway S, Xiong C, Benzinger T, Buckles V, Masters CL, Sperling R, Bateman RJ, Morris JC, Laske C; Dominantly Inherited Alzheimer Network (DIAN).

Alzheimers Dement. 2018 Nov;14(11):1427-1437. doi: 10.1016/j.jalz.2018.06.3059. Epub 2018 Sep 25.

PMID:
30266303
13.

White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease.

Araque Caballero MÁ, Suárez-Calvet M, Duering M, Franzmeier N, Benzinger T, Fagan AM, Bateman RJ, Jack CR, Levin J, Dichgans M, Jucker M, Karch C, Masters CL, Morris JC, Weiner M, Rossor M, Fox NC, Lee JH, Salloway S, Danek A, Goate A, Yakushev I, Hassenstab J, Schofield PR, Haass C, Ewers M.

Brain. 2018 Oct 1;141(10):3065-3080. doi: 10.1093/brain/awy229.

14.

Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease.

McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Holtzman DM, Cairns NJ, Goate AM, Marcus DS, Morris JC, Paumier K, Xiong C, Allegri R, Berman SB, Klunk W, Noble J, Ringman J, Ghetti B, Farlow M, Sperling RA, Chhatwal J, Salloway S, Graff-Radford NR, Schofield PR, Masters C, Rossor MN, Fox NC, Levin J, Jucker M, Bateman RJ; Dominantly Inherited Alzheimer Network.

Neurology. 2018 Oct 2;91(14):e1295-e1306. doi: 10.1212/WNL.0000000000006277. Epub 2018 Sep 14.

PMID:
30217935
15.

Human fibroblast and stem cell resource from the Dominantly Inherited Alzheimer Network.

Karch CM, Hernández D, Wang JC, Marsh J, Hewitt AW, Hsu S, Norton J, Levitch D, Donahue T, Sigurdson W, Ghetti B, Farlow M, Chhatwal J, Berman S, Cruchaga C, Morris JC, Bateman RJ; Dominantly Inherited Alzheimer Network (DIAN), Pébay A, Goate AM.

Alzheimers Res Ther. 2018 Jul 25;10(1):69. doi: 10.1186/s13195-018-0400-0.

16.

Discovery and validation of autosomal dominant Alzheimer's disease mutations.

Hsu S, Gordon BA, Hornbeck R, Norton JB, Levitch D, Louden A, Ziegemeier E, Laforce R Jr, Chhatwal J, Day GS, McDade E, Morris JC, Fagan AM, Benzinger TLS, Goate AM, Cruchaga C, Bateman RJ; Dominantly Inherited Alzheimer Network (DIAN), Karch CM.

Alzheimers Res Ther. 2018 Jul 18;10(1):67. doi: 10.1186/s13195-018-0392-9.

17.

Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease.

Lim YY, Hassenstab J, Goate A, Fagan AM, Benzinger TLS, Cruchaga C, McDade E, Chhatwal J, Levin J, Farlow MR, Graff-Radford NR, Laske C, Masters CL, Salloway S, Schofield P, Morris JC, Maruff P, Bateman RJ; Dominantly Inherited Alzheimer Network.

Ann Neurol. 2018 Sep;84(3):424-435. doi: 10.1002/ana.25299. Epub 2018 Aug 25.

PMID:
30014553
18.

Genetic variants associated with Alzheimer's disease confer different cerebral cortex cell-type population structure.

Li Z, Del-Aguila JL, Dube U, Budde J, Martinez R, Black K, Xiao Q, Cairns NJ; Dominantly Inherited Alzheimer Network (DIAN), Dougherty JD, Lee JM, Morris JC, Bateman RJ, Karch CM, Cruchaga C, Harari O.

Genome Med. 2018 Jun 8;10(1):43. doi: 10.1186/s13073-018-0551-4.

19.

Tau Kinetics in Neurons and the Human Central Nervous System.

Sato C, Barthélemy NR, Mawuenyega KG, Patterson BW, Gordon BA, Jockel-Balsarotti J, Sullivan M, Crisp MJ, Kasten T, Kirmess KM, Kanaan NM, Yarasheski KE, Baker-Nigh A, Benzinger TLS, Miller TM, Karch CM, Bateman RJ.

Neuron. 2018 May 16;98(4):861-864. doi: 10.1016/j.neuron.2018.04.035. No abstract available.

20.

A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer's disease.

Wang G, Berry S, Xiong C, Hassenstab J, Quintana M, McDade EM, Delmar P, Vestrucci M, Sethuraman G, Bateman RJ; Dominantly Inherited Alzheimer Network Trials Unit.

Stat Med. 2018 Sep 20;37(21):3047-3055. doi: 10.1002/sim.7811. Epub 2018 May 14.

PMID:
29761523
21.

White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease.

Lee S, Zimmerman ME, Narkhede A, Nasrabady SE, Tosto G, Meier IB, Benzinger TLS, Marcus DS, Fagan AM, Fox NC, Cairns NJ, Holtzman DM, Buckles V, Ghetti B, McDade E, Martins RN, Saykin AJ, Masters CL, Ringman JM, Fӧrster S, Schofield PR, Sperling RA, Johnson KA, Chhatwal JP, Salloway S, Correia S, Jack CR Jr, Weiner M, Bateman RJ, Morris JC, Mayeux R, Brickman AM; Dominantly Inherited Alzheimer Network.

PLoS One. 2018 May 9;13(5):e0195838. doi: 10.1371/journal.pone.0195838. eCollection 2018.

22.

Amyloid-β Plaques in Clinical Alzheimer's Disease Brain Incorporate Stable Isotope Tracer In Vivo and Exhibit Nanoscale Heterogeneity.

Wildburger NC, Gyngard F, Guillermier C, Patterson BW, Elbert D, Mawuenyega KG, Schneider T, Green K, Roth R, Schmidt RE, Cairns NJ, Benzinger TLS, Steinhauser ML, Bateman RJ.

Front Neurol. 2018 Mar 22;9:169. doi: 10.3389/fneur.2018.00169. eCollection 2018.

23.

Data-driven models of dominantly-inherited Alzheimer's disease progression.

Oxtoby NP, Young AL, Cash DM, Benzinger TLS, Fagan AM, Morris JC, Bateman RJ, Fox NC, Schott JM, Alexander DC.

Brain. 2018 May 1;141(5):1529-1544. doi: 10.1093/brain/awy050.

24.

Tau Kinetics in Neurons and the Human Central Nervous System.

Sato C, Barthélemy NR, Mawuenyega KG, Patterson BW, Gordon BA, Jockel-Balsarotti J, Sullivan M, Crisp MJ, Kasten T, Kirmess KM, Kanaan NM, Yarasheski KE, Baker-Nigh A, Benzinger TLS, Miller TM, Karch CM, Bateman RJ.

Neuron. 2018 Mar 21;97(6):1284-1298.e7. doi: 10.1016/j.neuron.2018.02.015. Erratum in: Neuron. 2018 May 16;98 (4):861-864.

PMID:
29566794
25.

Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.

Villeneuve S, Vogel JW, Gonneaud J, Pichet Binette A, Rosa-Neto P, Gauthier S, Bateman RJ, Fagan AM, Morris JC, Benzinger TLS, Johnson SC, Breitner JCS, Poirier J; Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) Research Group.

JAMA Neurol. 2018 May 1;75(5):608-619. doi: 10.1001/jamaneurol.2017.5135.

PMID:
29482212
26.

Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease.

Franzmeier N, Düzel E, Jessen F, Buerger K, Levin J, Duering M, Dichgans M, Haass C, Suárez-Calvet M, Fagan AM, Paumier K, Benzinger T, Masters CL, Morris JC, Perneczky R, Janowitz D, Catak C, Wolfsgruber S, Wagner M, Teipel S, Kilimann I, Ramirez A, Rossor M, Jucker M, Chhatwal J, Spottke A, Boecker H, Brosseron F, Falkai P, Fliessbach K, Heneka MT, Laske C, Nestor P, Peters O, Fuentes M, Menne F, Priller J, Spruth EJ, Franke C, Schneider A, Kofler B, Westerteicher C, Speck O, Wiltfang J, Bartels C, Araque Caballero MÁ, Metzger C, Bittner D, Weiner M, Lee JH, Salloway S, Danek A, Goate A, Schofield PR, Bateman RJ, Ewers M.

Brain. 2018 Apr 1;141(4):1186-1200. doi: 10.1093/brain/awy008.

27.

Reply to "Excess amyloid beta can be degraded in healthy humans".

Lucey BP, Hicks TJ, Elbert DL, Ovod V, Mawuenyega KG, Morris JC, Bateman RJ.

Ann Neurol. 2018 Mar;83(3):650-651. doi: 10.1002/ana.25185. Epub 2018 Mar 3. No abstract available.

PMID:
29457845
28.

Tau Positron Emission Tomography in Autosomal Dominant Alzheimer Disease: Small Windows, Big Picture.

McDade E, Bateman RJ.

JAMA Neurol. 2018 May 1;75(5):536-538. doi: 10.1001/jamaneurol.2017.4026. No abstract available.

PMID:
29435570
29.

Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study.

Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, Christensen J, McDade E, Wang G, Xiong C, Cairns NJ, Hassenstab J, Marcus DS, Fagan AM, Jack CR Jr, Hornbeck RC, Paumier KL, Ances BM, Berman SB, Brickman AM, Cash DM, Chhatwal JP, Correia S, Förster S, Fox NC, Graff-Radford NR, la Fougère C, Levin J, Masters CL, Rossor MN, Salloway S, Saykin AJ, Schofield PR, Thompson PM, Weiner MM, Holtzman DM, Raichle ME, Morris JC, Bateman RJ, Benzinger TLS.

Lancet Neurol. 2018 Mar;17(3):241-250. doi: 10.1016/S1474-4422(18)30028-0. Epub 2018 Feb 1.

PMID:
29397305
30.

Effect of sleep on overnight cerebrospinal fluid amyloid β kinetics.

Lucey BP, Hicks TJ, McLeland JS, Toedebusch CD, Boyd J, Elbert DL, Patterson BW, Baty J, Morris JC, Ovod V, Mawuenyega KG, Bateman RJ.

Ann Neurol. 2018 Jan;83(1):197-204. doi: 10.1002/ana.25117.

31.

Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies.

West T, Hu Y, Verghese PB, Bateman RJ, Braunstein JB, Fogelman I, Budur K, Florian H, Mendonca N, Holtzman DM.

J Prev Alzheimers Dis. 2017;4(4):236-241. doi: 10.14283/jpad.2017.36.

PMID:
29181488
32.

Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms.

Cruchaga C, Del-Aguila JL, Saef B, Black K, Fernandez MV, Budde J, Ibanez L, Deming Y, Kapoor M, Tosto G, Mayeux RP, Holtzman DM, Fagan AM, Morris JC, Bateman RJ, Goate AM; Dominantly Inherited Alzheimer Network (DIAN); Disease Neuroimaging Initiative (ADNI); NIA-LOAD family study, Harari O.

Alzheimers Dement. 2018 Feb;14(2):205-214. doi: 10.1016/j.jalz.2017.08.013. Epub 2017 Sep 21.

33.

Diversity of Amyloid-beta Proteoforms in the Alzheimer's Disease Brain.

Wildburger NC, Esparza TJ, LeDuc RD, Fellers RT, Thomas PM, Cairns NJ, Kelleher NL, Bateman RJ, Brody DL.

Sci Rep. 2017 Aug 25;7(1):9520. doi: 10.1038/s41598-017-10422-x.

34.

Loss of Brain Aerobic Glycolysis in Normal Human Aging.

Goyal MS, Vlassenko AG, Blazey TM, Su Y, Couture LE, Durbin TJ, Bateman RJ, Benzinger TL, Morris JC, Raichle ME.

Cell Metab. 2017 Aug 1;26(2):353-360.e3. doi: 10.1016/j.cmet.2017.07.010.

35.

A novel PSEN1 (S230N) mutation causing early-onset Alzheimer's Disease associated with prosopagnosia, hoarding, and Parkinsonism.

Ringman JM, Casado M, Van Berlo V, Pa J, Joseph-Mathurin N, Fagan AM, Benzinger T, Bateman RJ, Morris JC.

Neurosci Lett. 2017 Sep 14;657:11-15. doi: 10.1016/j.neulet.2017.07.046. Epub 2017 Jul 29.

36.

Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial magnetic resonance imaging study.

Kinnunen KM, Cash DM, Poole T, Frost C, Benzinger TLS, Ahsan RL, Leung KK, Cardoso MJ, Modat M, Malone IB, Morris JC, Bateman RJ, Marcus DS, Goate A, Salloway SP, Correia S, Sperling RA, Chhatwal JP, Mayeux RP, Brickman AM, Martins RN, Farlow MR, Ghetti B, Saykin AJ, Jack CR Jr, Schofield PR, McDade E, Weiner MW, Ringman JM, Thompson PM, Masters CL, Rowe CC, Rossor MN, Ourselin S, Fox NC; Dominantly Inherited Alzheimer Network (DIAN).

Alzheimers Dement. 2018 Jan;14(1):43-53. doi: 10.1016/j.jalz.2017.06.2268. Epub 2017 Jul 22.

37.

Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis.

Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, Sullivan M, Paumier K, Holtzman DM, Morris JC, Benzinger T, Fagan AM, Patterson BW, Bateman RJ.

Alzheimers Dement. 2017 Aug;13(8):841-849. doi: 10.1016/j.jalz.2017.06.2266. Epub 2017 Jul 19. Erratum in: Alzheimers Dement. 2017 Oct;13(10 ):1185.

38.

Stop Alzheimer's before it starts.

McDade E, Bateman RJ.

Nature. 2017 Jul 12;547(7662):153-155. doi: 10.1038/547153a. No abstract available.

PMID:
28703214
39.

Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease.

Brown BM, Sohrabi HR, Taddei K, Gardener SL, Rainey-Smith SR, Peiffer JJ, Xiong C, Fagan AM, Benzinger T, Buckles V, Erickson KI, Clarnette R, Shah T, Masters CL, Weiner M, Cairns N, Rossor M, Graff-Radford NR, Salloway S, Vöglein J, Laske C, Noble J, Schofield PR, Bateman RJ, Morris JC, Martins RN; Dominantly Inherited Alzheimer Network.

Alzheimers Dement. 2017 Nov;13(11):1197-1206. doi: 10.1016/j.jalz.2017.03.008. Epub 2017 May 11.

40.

Diurnal oscillation of CSF Aβ and other AD biomarkers.

Lucey BP, Fagan AM, Holtzman DM, Morris JC, Bateman RJ.

Mol Neurodegener. 2017 May 8;12(1):36. doi: 10.1186/s13024-017-0161-4.

41.

Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease.

Müller S, Preische O, Sohrabi HR, Gräber S, Jucker M, Dietzsch J, Ringman JM, Martins RN, McDade E, Schofield PR, Ghetti B, Rossor M, Graff-Radford NR, Levin J, Galasko D, Quaid KA, Salloway S, Xiong C, Benzinger T, Buckles V, Masters CL, Sperling R, Bateman RJ, Morris JC, Laske C.

Sci Rep. 2017 Apr 27;7(1):1225. doi: 10.1038/s41598-017-01327-w.

42.

The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkey.

Schoenfeld HA, West T, Verghese PB, Holubasch M, Shenoy N, Kagan D, Buono C, Zhou W, DeCristofaro M, Douville J, Goodrich GG, Mansfield K, Saravanan C, Cumin F, Webb RL, Bateman RJ.

Toxicol Appl Pharmacol. 2017 May 15;323:53-65. doi: 10.1016/j.taap.2017.03.014. Epub 2017 Mar 15.

43.

Associations Between β-Amyloid Kinetics and the β-Amyloid Diurnal Pattern in the Central Nervous System.

Lucey BP, Mawuenyega KG, Patterson BW, Elbert DL, Ovod V, Kasten T, Morris JC, Bateman RJ.

JAMA Neurol. 2017 Feb 1;74(2):207-215. doi: 10.1001/jamaneurol.2016.4202.

44.

Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury.

Suárez-Calvet M, Araque Caballero MÁ, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, Levin J, Danek A, Ewers M, Haass C; Dominantly Inherited Alzheimer Network.

Sci Transl Med. 2016 Dec 14;8(369):369ra178.

45.

Soluble Amyloid-beta Aggregates from Human Alzheimer's Disease Brains.

Esparza TJ, Wildburger NC, Jiang H, Gangolli M, Cairns NJ, Bateman RJ, Brody DL.

Sci Rep. 2016 Dec 5;6:38187. doi: 10.1038/srep38187.

46.

Human Central Nervous System (CNS) ApoE Isoforms Are Increased by Age, Differentially Altered by Amyloidosis, and Relative Amounts Reversed in the CNS Compared with Plasma.

Baker-Nigh AT, Mawuenyega KG, Bollinger JG, Ovod V, Kasten T, Franklin EE, Liao F, Jiang H, Holtzman D, Cairns NJ, Morris JC, Bateman RJ.

J Biol Chem. 2016 Dec 30;291(53):27204-27218. doi: 10.1074/jbc.M116.721779. Epub 2016 Oct 28.

47.

Clinical, imaging, pathological, and biochemical characterization of a novel presenilin 1 mutation (N135Y) causing Alzheimer's disease.

Natelson Love M, Clark DG, Cochran JN, Den Beste KA, Geldmacher DS, Benzinger TL, Gordon BA, Morris JC, Bateman RJ, Roberson ED.

Neurobiol Aging. 2017 Jan;49:216.e7-216.e13. doi: 10.1016/j.neurobiolaging.2016.09.020. Epub 2016 Oct 3.

48.

Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).

Tang M, Ryman DC, McDade E, Jasielec MS, Buckles VD, Cairns NJ, Fagan AM, Goate A, Marcus DS, Xiong C, Allegri RF, Chhatwal JP, Danek A, Farlow MR, Fox NC, Ghetti B, Graff-Radford NR, Laske C, Martins RN, Masters CL, Mayeux RP, Ringman JM, Rossor MN, Salloway SP, Schofield PR, Morris JC, Bateman RJ; Dominantly Inherited Alzheimer Network (DIAN).

Lancet Neurol. 2016 Dec;15(13):1317-1325. doi: 10.1016/S1474-4422(16)30229-0. Epub 2016 Oct 21. Review. Erratum in: Lancet Neurol. 2017 Jan;16(1):24.

49.

Correction: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group.

Su Y, Blazey TM, Owen CJ, Christensen JJ, Friedrichsen K, Joseph-Mathurin N, Wang Q, Hornbeck RC, Ances BM, Snyder AZ, Cash LA, Koeppe RA, Klunk WE, Galasko D, Brickman AM, McDade E, Ringman JM, Thompson PM, Saykin AJ, Ghetti B, Sperling RA, Johnson KA, Salloway SP, Schofield PR, Masters CL, Villemagne VL, Fox NC, Förster S, Chen K, Reiman EM, Xiong C, Marcus DS, Weiner MW, Morris JC, Bateman RJ, Benzinger TL; Dominantly Inherited Alzheimer Network.

PLoS One. 2016 Sep 20;11(9):e0163669. doi: 10.1371/journal.pone.0163669. eCollection 2016.

50.

The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model.

Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM, Fanning K, Farlow MR, Hassenstab J, McDade EM, Mills S, Paumier K, Quintana M, Salloway SP, Santacruz A, Schneider LS, Wang G, Xiong C; DIAN-TU Pharma Consortium for the Dominantly Inherited Alzheimer Network.

Alzheimers Dement. 2017 Jan;13(1):8-19. doi: 10.1016/j.jalz.2016.07.005. Epub 2016 Aug 29.

Supplemental Content

Loading ...
Support Center